|
Ranganathan, S; Benetatos, C A; Colarusso, P J et al. (1998) Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77:562-6
|
|
Ranganathan, S; Dexter, D W; Benetatos, C A et al. (1998) Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta 1395:237-45
|
|
Ranganathan, S; Salazar, H; Benetatos, C A et al. (1997) Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate 30:263-8
|
|
Hudes, G R; Nathan, F; Khater, C et al. (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156-63
|
|
Hudes, G (1997) Estramustine-based chemotherapy. Semin Urol Oncol 15:13-9
|
|
Ranganathan, S; Dexter, D W; Benetatos, C A et al. (1996) Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56:2584-9
|
|
Hudes, G R; Obasaju, C; Chapman, A et al. (1995) Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol 22:6-11
|
|
Hudes, G R; Nathan, F E; Khater, C et al. (1995) Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 22:41-5
|
